he aneurysm than were the complex (CASHMERE®) and helical (HELIPAQ®) coils. The average packing density for DELTAPAQ (39.1 %) was significantly higher than the complex (35.2%) and helical (32.2 %) coil systems. In addition, DELTAPAQ had the highest rate of angiographic occlusion (Class 1) based on the Raymond score, a qualitative measure of permeability.
"This study encourages clinicians and industry to look at the coil uniformity index, in addition to packing density and occlusion rates, when deciding which endovascular coil to use," said Karen Prange, General Manager and Vice President, Codman Neurovascular. "Codman remains committed to design innovation and supporting research that advances the understanding of neurovascular care. We are pleased to see that the DELTAWIND technology performed favorably in this assessment model."
The study was funded by a research grant from Micrus Endovascular, Inc. which now operates under Codman Neurovascular, a Codman business.
In addition to Dr. Bendok, study authors include: Manik Mehra, MD, Matthew J. Gounis, PhD, and Robert M. King, BS, from the New England Center for Stroke Research, University of Massachusetts Medical School; Ali Shaibani, MD, Michael C. Hurley, MD, and Guilherme Dabus, MD, from Northwestern University's Feinberg School of Medicine; Elad I. Levy, MD, School of Medicine and Biomedical Sciences, University of New York, Buffalo; and Fatimaezzahra E. Labdag, BS, from Micrus Endovascular, Inc.
Endovascular coils are inserted directly into an aneurysm through a microcatheter, a small, thin, hollow tube, to block blood flow and prevent rupture, which could lead to a hemorrhagic stroke, a life-threatening condition that affects about 13 percent of the 800,000 stroke cases each year in the United States. (2) According to the American Stroke Association, cerebral aneurysms affect 3 to 5 million people in the United Sta
Page: 1 2 3 Related medicine technology :1
|SOURCE Codman & Shurtleff, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients2
. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer3
. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain4
. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma5
. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor6
. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-7967
. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD8
. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study9
. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression10
. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus11
. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes